

**ALL INDIA INSTITUTE OF MEDICAL SCIENCES
NATIONAL CANCER INSTITUTE
(STORE SECTION)**

Date: 11.08.2026


Subject: Inviting objections/comments/suggestions, if any, regarding proprietary (PAC) nature of Tab. Belumosudil 200mg for EHS Patient Dr ALAN SHAJI through Proprietary basis under Rule-166(ii) of GFR, 2017 (PAC) - reg.

Store Section, NCI is in process to procure Tab. Belumosudil 200mg for EHS Patient Dr ALAN SHAJI through Proprietary basis under Rule-166(iii) of GFR, 2017 (PAC) as per the requirement submitted by the concerned user department.

In this regard, objections/comments/suggestions, if any, regarding proprietary (PAC) nature Tab. Belumosudil 200mg is invited from eligible manufacturers/authorized distributors/suppliers having capability to supply equivalent compatible consumables may be submitted to the office of the undersigned i.e. Senior Store Officer Room, NCI-AIIMS, Badsa, Jhajjar, Pin Code-124105 latest by 26.08.2026, 05:00pm. Any representation/objection beyond 26.08.2026, 05:00pm will not be considered.

The objections/comments/suggestions should be supported with documents, and other necessary credentials demonstrating equivalence with the required item for Tab. Belumosudil 200mg through Proprietary basis at Store Section, NCI-Jhajjar.

If no objections/comments/suggestions are received within the stipulated period, it will be assumed that no manufacturers/authorized distributors/suppliers have objection to the above mentioned proprietary (PAC) nature of the said item and the procurement process will be initiated accordingly.


Senior Store Officer

VSM
11-8-26

11/8/26

ALL INDIA INSTITUTE OF MEDICAL SCIENCES
NATIONAL, CANCER INSTITUTE
JHAJJAR, HARYANA-124105

PROPRIETARY/SPECIFIC BRAND GOODS CERTIFICATE

1. Item / Type / Model No. required along with specification	Tab. Belumosidil
2. Is the item a spare part attachment or accessory for an existing equipment	Not applicable
3. Name of the manufactures/supplier of the item proposed by the indenter	Sanofi
4. Are the sole manufactures/sole distributors of the item	Yes
5. Is there any other item with similar/equipment specification available in the market to meet the job requirement envisaged. Of the answer is yes, why the same can't be procured.	No
6. What were the efforts made to locate alternative source of supply or use other substitutes	Online search Patent has not expired
7. Why open/limited tender can't be resorted to, for locating alternative source	Only company do manufacture this comp.
8. Are the proprietary & close system items certifying that the rates are reasonable or not.	Reasonable
9. Any other justification for procuring item for single source.	Life saving

I/we have assessed the market and I/we do hereby certify that item No.01 is a Proprietary item of the manufacture Sanofi and cannot be substituted with a similar item from other vendor for its intended use.

14/07/2020
डॉ. रंजित कुमार साहू / DR. RANJIT KUMAR SAHOO
गोपबन्धु / Professor
चिकित्सा अतुल्यविज्ञान विभाग / Dept. of Medical Oncology
डॉ. पी. आर. ए. आई. आर. सी. एच., अ.भा.आ.सं.
Dr. B.R.A. IRCH (AIIMS)
नई दिल्ली - 110029 / New Delhi-20

sanofi

Ref.: INST/AIIMSDel/26-27/06

9th June, 2026

To,
The Store Officer (H)
All India Institute of Medical Sciences
New Delhi-110029

Dear Sir,

Sub: Budgetary Quotation

We are pleased to share our best possible rates for our below product :

S. No.	Brand	Composition	MRP	Basic Rate (Excluding GST)	GST	Final Amount (Including GST)
1	Rezurock	Belumosudil Tab 200mg	Rs. 6,35,560.00 (bottle of 30 tabs)	Rs.2,92,000.00 (bottle of 30 tabs)	0%	Rs.2,92,000.00 (bottle of 30 tabs)

The above mentioned rates are valid for 6 months from the Quotation issuance date.

We confirm the details of our authorized distributor for the same as under :

M/s. Aark Pharmaceuticals Private Ltd.

S-14, Ground & First Floor,
Uphaar Cinema Complex Market, Green
Park Extension, New Delhi-110016.

Kindly do the needful and confirm.

Thanking you,

Yours sincerely,
for Sanofi Healthcare India Pvt. Ltd.



Sangita Salunke
Authorised Signatory

sanofi

Date: 8th June 2026

PROPRIETARY ARTICLE CERTIFICATE

To Whom It May Concern

We take this opportunity to inform you that Sanofi Healthcare India Pvt. Ltd is a company, incorporated in India and belongs to the Sanofi Group. Sanofi is a global healthcare leader focused on patients' needs.

Sanofi has a diversified offering in medicines, vaccines and innovative therapeutic solutions. We are engaged in research, development, manufacturing and marketing of healthcare products, with presence in over 100 countries.

Rezurock® (Belumosudil Tablets 200mg) is imported and marketed in India by Sanofi Healthcare India Pvt. Ltd.

The above-mentioned product is the original research and proprietary product of Sanofi Group.

We will be happy to provide you any further information on our products that you may require. You may also visit our website www.Sanofi.in

Yours truly,



Jeena Cyril
Head- Regulatory Affairs
Sanofi Healthcare India Pvt. Ltd

Rezurock local PAC

Final Audit Report

2026-06-08

Created:	2026-06-08 (Brasilia Standard Time)
By:	Ranita Vaze (Ranita.Vaze@sanofi.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAAzTvmfUDgjPq3Y-R52Cy-RV_LrS1mfILl
Documents:	Rezurock local PAC.pdf (1 page)
Number of Documents:	1
Document page count:	1
Number of supporting files:	0
Supporting files page count:	0

"Rezurock local PAC" History

-  Document created by Ranita Vaze (Ranita.Vaze@sanofi.com)
 Documents: Rezurock local PAC.pdf
 2026-06-08 - 01:03:31 ADT- IP address: 165.225.121.41
-  Document emailed to Jeena Cyril (jeena.cyril@sanofi.com) for signature
 2026-06-08 - 01:03:59 ADT
-  Email viewed by Jeena Cyril (jeena.cyril@sanofi.com)
 2026-06-08 - 01:04:43 ADT- IP address: 185.150.84.36
-  Agreement viewed by Jeena Cyril (jeena.cyril@sanofi.com)
 Documents: Rezurock local PAC.pdf
 2026-06-08 - 01:04:44 ADT- IP address: 185.150.84.36
-  Document e-signed by Jeena Cyril (jeena.cyril@sanofi.com)
 Documents: Rezurock local PAC.pdf
 Signature Date: 2026-06-08 - 01:04:59 ADT - Time Source: server- IP address: 167.103.2.167 - Signature appearance selected: IMAGE
-  Agreement completed.
 2026-06-08 - 01:04:59 ADT

sanofi

Powered by
Adobe
 Acrobat Sign